ICH Q12 기반 허가 후 변경관리 제도의 국가별 도입·운영 비교 : 미국·유럽연합·일본·캐나다·대한민국을 중심으로
Comparative Analysis of ICH Q12-Based Post-Approval Change Management Systems Across Five Regulatory Authorities : the United States, European Union, Japan, Canada, and the Republic of Korea
This study compares the adoption of three key post-approval CMC change management tools defined in ICH Q12—Established Conditions (EC), Post-Approval Change Management Protocol (PACMP), and Product Lifecycle Management (PLCM)—across five regulatory authorities: the United States (FDA), the European Union (EMA), Japan (MHLW/PMDA), Canada (HC), and the Republic of Korea (MFDS). A comparative analysis of laws and guidelines published through January 2026 was conducted, focusing on risk-based change categorization, the regulatory integration of Q12 tools, and the existence of pilot programs. While all five authorities apply riskbased principles, the extent of Q12 tool adoption varies considerably. The United States has institutionalized all three tools through legislation and internal policies. The EU and Japan have substantially advanced PACMP implementation, whereas Canada remains in a phased adoption stage. Korea operates a risk-based, CTD-linked review system but lacks explicit legal or procedural frameworks for any of the three tools. This study proposes a phased adoption strategy through pilot programs and the extension of Korea's pre-submission consultation system to post-approval change management, thereby enhancing regulatory predictability and strengthening the global competitiveness of the Korean pharmaceutical industry.
목차
Abstract I. 서론 II. 연구 방법 III. 연구 결과 1. 국가별 변경등급 분류체계 비교 2. ICH Q12 주요 도구의 국가별 채택 현황 IV. 고찰 V. 결론 참고문헌
한국에프디시규제과학회(구 한국에프디시법제학회) [The Korean Society of Food, Drug and Cosmetic Regulatory Sciences]
설립연도
2006
분야
의약학>약학
소개
본회는 의약품, 의약외품, 의료기기, 화장품 및 건강기능식품 등과 관련된 국내·외의 각종 법령과 규정 등에 대한 연구와 발표 등을 통하여 합리적이고 투명한 법령과 규정의 제·개정 및 정책개발에 기여함으로써 관련 산업의 발전과 국민의 건강증진에 기여하며 회원 상호 간의 친목을 도모함을 목적으로 한다.
간행물
간행물명
KFDC규제과학회지(구 FDC법제연구) [Regulatory Research on Food, Drug and Cosmetic]